SecBot SecBot
PRESS-RELEASE ·Filed Jun 19, 2026

IOVA

Iovance Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

This is a routine new-hire equity grant with negligible dilution. No trading action warranted; monitor for any future updates on clinical or commercial progress for Amtagvi.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.06
T+0 close · Jun 19, 2026 · via day close
Latest settled
+130.54%
T+60 · $9.36
Vs SPY
+128.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $4.06entry
  2. T+1 · 5mo ago +9.36%α +10.81% · $4.44
  3. T+5 · 5mo ago +4.68%α +6.75% · $4.25
  4. T+20 · 4mo ago +23.15%α +23.30% · $5.00
  5. T+60 · 2mo ago +130.54%α +128.80% · $9.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under its 2021 Inducement Plan, with an exercise price of $3.91 per share and a three-year vesting schedule. This is a routine equity grant to attract new hires and has no material impact on the company's financials or operations.

Key Facts

  • Granted inducement stock options for 140,860 shares to 27 new non-executive employees.
  • Exercise price set at $3.91, the closing price on June 18, 2026.
  • Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
  • Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).

Financial Impact

140,860 shares represent approximately 0.1% of outstanding shares (based on ~140M shares outstanding); no material financial impact.

dilution

Risk Factors

  • Minimal dilution from option exercises if stock price appreciates.
  • No impact on near-term revenue or pipeline catalysts.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3314899

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 19, 2026